Loading...
•
Jun 30, 2020
Ironwood Pharmaceuticals Q2 2020 Earnings Report
Reported GAAP net income and grew LINZESS total prescription demand.
Key Takeaways
Ironwood Pharmaceuticals reported a solid quarter with GAAP net income of $25 million and adjusted EBITDA of $33 million. LINZESS total prescription demand grew by 9% year-over-year.
Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million
Grew LINZESS® (Iinaclotide) total prescription demand by 9% year-over-year
New-to-brand prescription demand grew >15% in June 2020 compared to March 2020
Reinstating full year 2020 total revenue and LINZESS net sales growth guidance; reiterating adjusted EBITDA guidance
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood is reinstating full year 2020 total revenue and LINZESS net sales growth guidance and reiterating adjusted EBITDA guidance.